5 data read out in the next 6 months
Phase 3 trial in GBM started in Jan 2021 - fully funded
Kazia starting NDA application
US$30 million CASH
Kazia Licenses Rights to Cantrixil to Oasmia for US$4 million up front, and development milestones worth up to US$42 million and double-digit sales royalties.
Kazia Licenses Rights to Paxalisib in Greater China to Simcere for US$ 11 million and milestone payments of up to US$ 281 million plus
mid-teen percentage royalties on commercial sales for GBM only
Kazia Licenses Rights to Paxalisib outside Greater China for US $X billion and double-digit sales royalties in GBM only
Kazia Licenses Rights to Paxalisib for US $X billion and double-digit sales royalties outside GBM
